Dr. Paaladinesh Thavendiranathan, MD
Claim this profileUniversity Health Network
Studies Heart Failure
Studies Cancer
2 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Paaladinesh Thavendiranathan, MD is currently running
Stopping Heart Medications
for Cancer Survivors
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable long-term pill burden, financial costs, and side-effects (e.g., dizziness and fatigue). As a result, cancer survivors frequently ask if they can safely stop their heart failure medications once their heart function has returned to normal. Currently there is no scientific evidence in this area of Cardio-Oncology. To address this knowledge gap, the investigators have designed a randomized control trial to assess the safety of stopping heart failure medication in patients with CTRCD and recovered heart function. The investigators will enrol patients who have completed their cancer therapy and are on heart medications for their CTRCD, which has now normalized. The investigators will randomize patients with no other reasons to continue heart failure medications (e.g., kidney disease) to continuing or stopping their heart medications safely. All patients will undergo a cardiac MRI at baseline, 1 and 5 years with safety assessments at 6-8 weeks, 6 months and 3 and 5 years. The investigators will determine if stopping medications is non-inferior to continuing medications by counting the numbers of patients who develop heart dysfunction by 1 year in each group.
Recruiting3 awards Phase 4
Rehabilitation
for Cancer Survivors
Pediatric, adolescent and young adult cancer survivors (PAYA-CS) are at higher risk of cardiovascular (CV) morbidity and mortality. This is a consequence of prior cancer-related therapies that have the potential of producing cardiac dysfunction, reducing cardiorespiratory fitness (reduced VO2peak) and psychosocial morbidities (i.e., anxiety and depression). A reduction of physical activity levels can evoke functional limitations resulting in a vicious cycle of reduced exercise tolerance and physical deterioration. To date, there is limited evidence on the use of non-pharmacological strategies such as Cardio-Oncology Rehabilitation (CORE) including structured exercise, behavioural support and risk factor management to improve the outcomes of this underserved population. The HIMALAYAS study is a randomized controlled trial designed to evaluate the impact of a CORE intervention (consisting of six-months home and onsite-based structured moderate to high-intensity aerobic exercise training and CVD risk factor management) on CV and psychosocial health, and the cardiovascular disease risk in PAYA-CS with mild heart dysfunction (stage B heart failure) compared to standard of care (i.e. providing guidance on the current exercise recommendations for cancer survivors). The primary objective of the HIMALAYAS study is to determine whether a six-month supervised CORE intervention, consisting of individualized moderate to high-intensity aerobic exercise training, CVD risk factor modification and enhanced online behavioral support, improves cardiorespiratory fitness (VO2peak; primary outcome), cardiac function, CVD risk factors and biomarkers, and patient-reported outcomes (PROs) at six- months follow-up compared to standard of care (CON) in PAYA-CS with stage B heart failure. The secondary objective is to assess the same outcomes at 12- and 24-months follow-up. We will recruit 336 patients across 5 sites in Canada and upto 134 patients at UHN in 3 years and conclude in 6 years.
Recruiting1 award N/A5 criteria
More about Paaladinesh Thavendiranathan, MD
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Paaladinesh Thavendiranathan, MD has experience with
- Stopping Heart Failure Medication(s)
- Cardio-oncology Rehabilitation (CORE)
- Exercise Guidelines For Cancer Survivors (ExGL)
- PAI Group (PAI)
Breakdown of trials Paaladinesh Thavendiranathan, MD has run
Cardiac Toxicity
Antineoplastic Toxicity
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paaladinesh Thavendiranathan, MD specialize in?
Paaladinesh Thavendiranathan, MD focuses on Heart Failure and Cancer. In particular, much of their work with Heart Failure has involved treating patients, or patients who are undergoing treatment.
Is Paaladinesh Thavendiranathan, MD currently recruiting for clinical trials?
Yes, Paaladinesh Thavendiranathan, MD is currently recruiting for 2 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Paaladinesh Thavendiranathan, MD has studied deeply?
Yes, Paaladinesh Thavendiranathan, MD has studied treatments such as Stopping Heart Failure Medication(s), Cardio-oncology Rehabilitation (CORE), Exercise Guidelines for Cancer Survivors (ExGL).
What is the best way to schedule an appointment with Paaladinesh Thavendiranathan, MD?
Apply for one of the trials that Paaladinesh Thavendiranathan, MD is conducting.
What is the office address of Paaladinesh Thavendiranathan, MD?
The office of Paaladinesh Thavendiranathan, MD is located at: University Health Network, Toronto, Ontario M5G2C4 Canada. This is the address for their practice at the University Health Network.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.